There are 110 clinical-stage psychedelic drug stocks trading on North American stock exchanges (see here) of which 64 research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (see here), 40 research the treatment of illnesses based on the use of THC marijuana and 6 are focused on the development and operation of treatment clinics. 

The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index are those that have market caps in excess of $50M and they went UP 9.8% this week and are now UP 49.5% since the end of June albeit DOWN 32.6% YTD.

Below is how the constituents have performed since the end of June, in descending order, along with their performances YTD:

1. Cybin (CYBN): UP 80.4% since the end of June; still DOWN 57.3% YTD
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
2. Seelos (SEEL): UP 77.9% since the end of June; still DOWN 25.8% YTD
   • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
3. Compass Pathways (CMPS): UP 61.9% since the end of June; still DOWN 20.7% YTD
   • focused on the development of a new model of psilocybin therapy for people with treatment-resistant depression, in which psilocybin is administered in conjunction with psychological support.
4. GH Research (GHRS): UP 49.3% since the end of June; still DOWN 36.1% YTD
   • focused on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
5. Atai (ATAI): UP 28.6% since the end of June; still DOWN 38.7% YTD
   • focused on acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
6. Mind Medicine (MNMD): UP 23.4% since the end of June; still DOWN 42.8% YTD
   • focused on discovering, developing, and deploying the next generation of psychedelic-inspired medicines and therapies to address addiction and mental illness development.
7. Zynerba (ZYNE): UP 7.9% since the end of June; still DOWN 57.3% YTD
   • focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.
8. Allied Corp. (ALID): DOWN 12.5% since the end of June; now DOWN 76.3% YTD
   • focused on the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.

In total, the munKNEE Psychedelic Compounds-Based Drug Stock Index went UP 9.8% this week, is UP 49.5% since the end of June, but is still DOWN 32.6% YTD.

In the opening paragraph I alluded to 6 psychedelic companies that are focused on the development, expansion and operation of therapy clinics to capitalize on the massive commercial opportunity to treat the plus two billion people worldwide, according to Data Bridge Market Research, who suffer from chronic pain, addiction/substance abuse withdrawal, and depression. 5 of these 6 companies are currently using the psychedelic compound ketamine (see here) which is legal in the U.S. and Canada, having been used for years as an anesthetic in veterinary clinics, while the other is planning to open clinics in Canada using ibogaine.

Below is a description of each of the commercialization developments, market capitalizations and price performances of the companies operating such psychedelic-assisted therapy (PAT) clinics since the end of June, in descending order, and YTD where applicable:

1. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
   • has three (3) clinics in Canada (Vancouver, Montreal, and Toronto) centered on the use of ketamine in its therapies but also with the ability to undertake treatments using psilocybin and MDMA (3,4-methylenedioxymethamphetamine, more commonly known by its street drug name, "Ecstasy" or "Molly" - short for 'molecular') as authorized by a Special Access Program regulated by Health Canada that allows people to access certain medications that are not yet authorized or available to the general public;
   • has six (6) clinics in Utah and two (2) in Arizona utilizing ketamine-assisted therapy;
   • has a market capitalization of C$59M, is +31.6% since the end of June but is still -40.5% YTD.
2. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
   • is concentrating on the treatment of Alcohol Use Disorder with ketamine and has three (3) fully-operational ketamine-assisted therapy clinics, two (2) in the U.K. and one (1) in Norway, expects to open two (2) more in Manchester and Dublin in 2023 and have 20 clinics in operation by 2024 generating more than $100M in revenue;
   • has signed a licensing partnership agreement with Wellbeings® Pain Management and Dependency Clinic which will enable Ontario based Wellbeings® to treat their patients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUD as a co-morbidity for pain. The terms call for Awakn to provide access to its proprietary therapeutics for AUD and training to Wellbeings practitioners and for Wellbeings to pay Awakn an annual subscription and a revenue share per treatment;
   • has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (see below). The current license agreement calls for Awakn to provide access to its proprietary ketamine as well as training to Revitalist practitioners in return for which, Revitalist will pay Awakn an annual fee and a revenue share per treatment;
   • has a market capitalization of $15M, is +22.9% since the end of June but is still  -79.0% YTD.
3. Delic Corp. (CSE: DELC|OTCQB: DELCF)
   • has the largest number of psychedelic wellness clinics in the U.S. with three (3) in Arizona, two (2) in Texas, two (2) in Nevada, and one (1) each in Colorado, Florida, Illinois, Minnesota, Utah and Washington;
   • has a market capitalization of C$5M, is unchanged in price since the end of June and is -60% YTD.
4. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF)
   • provides ketamine-assisted psychotherapy and other novel treatments through its network of ten (10) integrative mental health clinics operating in six (6) states and nine (9) options on other clinics;
   • has a market capitalization of $5M, is -14.3% since the end of June and is now -62.5% YTD.
5. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
   • is concentrating on the treatment of Opioid Use Disorder with ibogaine, a naturally-occurring molecule derived from the root bark of the iboga tree and other plants, which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization;
   • has acquired the revenue-generating Kelburn Addiction Recovery Center practice in Winnipeg, Manitoba, Canada, with the intention of developing a state-of-the-art comprehensive and holistic addiction management care model which will be rolled out to future Universal Ibogaine clinics in Canada, the U.S. and internationally, and to be further monetized by offering training and franchising;
   • has a market capitalization of C$6.7M, is -25% since the end of June, N/A YTD.
6. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF)
   • is concentrating on therapies for treatment resistant depression, post-traumatic stress disorder as well as disorders affecting the central nervous systems;
   • operates ketamine-assisted psychotherapy clinics in Canada (3), the U.S. (8) and Europe (1);
   • has undergone a corporate reorganization that culminated in the spinout of the Company from its former parent entity Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.) on August 17th and listing on the TSXV under the trading symbol FTHW. Reunion continues to hold 21.84% of Field Trip common shares;
   • has a market capitalization of $23M but has no comparative pricing having been just listed as a separate entity this past week.

More By This Author:

Upward Trend In American Cannabis Stocks Stalled Last Week
Upward Trend In Canadian Cannabis Stocks Stalled Last Week
Plant-Based Food Stocks Index Last Week By 15%; Its Biggest Names Down Most